In Vivo Testing and Statistics Core

体内测试和统计核心

• 批准号: 6985635
• 负责人: DONNA M. BOULEY
• 金额: $ 14.5万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-04-01 至 2009-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6985635
• 关键词: antineoplastics; biomedical facility; blood chemistry; data management; drug screening /evaluation; histopathology; human tissue; laboratory mouse; neoplasm /cancer; neoplasm /cancer radiation therapy; neoplasm /cancer therapy; neoplastic cell; nonhuman therapy evaluation; statistical service /center; statistics /biometry; tissue /cell preparation; tissue /organ preservation; tissue resource /registry

This core has three goals. The first is to provide expert and uniform in vivo evaluation of the compounds that are judged worthy of evaluation from in vitro testing. This core will also provide all of the normal tissue toxicology testing. All the tumor testing will be performed with the HT29/Ak human tumor transplanted into nu/nu mice. The normal tissue toxicology testing will be performed with the nu/nu mice beating the HT29 tumor (because of the possibility of active drug "leaking" into the vasculature from the tumor), and with CD1 mice (without tumors). The second goal of the project is to provide a centralized cell line, medium and serum bank to each project to ensure uniformity as much as possible between the test systems used by all of the projects. The Core will also perform the serum testing and mycoplasma testing of the cell lines used by all the projects. The third goal is to provide statistical and database support for all of the projects in the Program Project.

该核心有三个目标。首先是对值得从体外测试中评估的化合物进行体内评估专家和统一的评估。该核心还将提供所有正常的组织毒理学测试。所有肿瘤测试将使用移植到NU/NU小鼠的HT29/AK人类肿瘤进行。正常的组织毒理学测试将使用击败HT29肿瘤的NU/NU小鼠进行（因为可能有活性药物从肿瘤中“泄漏”到脉管系统中）以及CD1小鼠（无肿瘤）。该项目的第二个目标是为每个项目提供集中式单元线，中等和血清库 在所有项目使用的测试系统之间尽可能确保均匀性。核心还将对所有项目使用的细胞系进行血清测试和支原体测试。第三个目标是为程序项目中的所有项目提供统计和数据库支持。